Scarica l'app Stockscreener
40.86
1.44%
0.60
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$40.26
Aprire:
$40.55
Volume 24 ore:
166.91K
Relative Volume:
0.05
Capitalizzazione di mercato:
$17.47B
Reddito:
$2.31B
Utile/perdita netta:
$1.66B
Rapporto P/E:
17.79
EPS:
2.297
Flusso di cassa netto:
$827.02M
1 W Prestazione:
+5.10%
1M Prestazione:
+7.22%
6M Prestazione:
+13.86%
1 anno Prestazione:
+55.88%
Intervallo 1D:
$40.44
$40.92
Intervallo di 1 settimana:
$38.51
$41.70
Portata 52W:
$27.47
$41.70
Royalty Pharma Plc Stock (RPRX) Company Profile
Nome
Royalty Pharma Plc
Settore
Industria
Telefono
(212) 883-0200
Indirizzo
110 EAST 59TH STREET, NEW YORK, NY
Confronta RPRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
40.90 | 17.20B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.52 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.38 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.11 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
808.13 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
172.94 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-30 | Iniziato | Goldman | Buy |
| 2025-05-16 | Iniziato | Morgan Stanley | Overweight |
| 2024-06-03 | Downgrade | UBS | Buy → Neutral |
| 2022-06-14 | Ripresa | UBS | Buy |
| 2022-05-13 | Iniziato | Scotiabank | Sector Outperform |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-14 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-07-30 | Iniziato | Tigress Financial | Buy |
| 2020-11-09 | Aggiornamento | UBS | Neutral → Buy |
| 2020-07-14 | Iniziato | Evercore ISI | In-line |
| 2020-07-13 | Iniziato | BofA Securities | Buy |
| 2020-07-13 | Iniziato | Citigroup | Neutral |
| 2020-07-13 | Iniziato | Cowen | Outperform |
| 2020-07-13 | Iniziato | Goldman | Neutral |
| 2020-07-13 | Iniziato | JP Morgan | Neutral |
| 2020-07-13 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Iniziato | SunTrust | Buy |
| 2020-07-13 | Iniziato | UBS | Neutral |
Mostra tutto
Royalty Pharma Plc Borsa (RPRX) Ultime notizie
Royalty Pharma increases quarterly dividend by 6.8% to $0.235 - Investing.com India
Royalty Pharma Increases Quarterly Dividend to $0.235 a Share From $0.22, Payable March 10 to Holders of Record on Feb. 20. - MarketScreener
Royalty Pharma Declares Q1 2026 Dividend of $0.235 per Share, Marking 6.8% Increase - Quiver Quantitative
Royalty Pharma raises quarterly dividend by 6.8% to $0.235/share - MSN
Royalty Pharma Announces Dividend Increase - The Manila Times
Royalty Pharma plc (RPRX) Raises Quarterly Dividend 7.3% to $0.235; 2.3% Yield - StreetInsider
Royalty Pharma Announces Dividend Increase - Benzinga
Moran Wealth Management LLC Increases Position in Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma plc stock supported by strong cash flowsInflation Watch & Stock Timing and Entry Methods - ulpravda.ru
Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi - MSN
Trade Report: How risky is Royalty Pharma plc (RPD) stock compared to peersPortfolio Value Summary & Free Expert Verified Stock Movement Alerts - ulpravda.ru
Is Royalty Pharma plc stock affected by interest rate hikesJuly 2025 Opening Moves & Growth Oriented Trade Recommendations - ulpravda.ru
Is Royalty Pharma plc stock ready for breakoutJuly 2025 Technicals & Short-Term Swing Trade Alerts - ulpravda.ru
170,604 Shares in Royalty Pharma PLC $RPRX Bought by Hosking Partners LLP - MarketBeat
Royalty Pharma PLC $RPRX Shares Bought by Robeco Institutional Asset Management B.V. - MarketBeat
Royalty Pharma stock hits 52-week high at $41.26 By Investing.com - Investing.com Nigeria
Royalty Pharma stock hits 52-week high at $41.26 - Investing.com India
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's Why - MarketBeat
Royalty Pharma shares edge higher on acquisition of oncology drug royalties - MSN
United StatesGoodwin Guides Royalty Pharma On Acquisition Of Remaining Royalty Interest In Roche’s Evrysdi For $240 Million And Potential Milestones - Mondaq
Royalty Pharma plc (NASDAQ:RPRX) Nasdaq Index Life Sciences Partner - Kalkine Media
Financiere des Professionnels Fonds d investissement inc. Invests $933,000 in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones - citybiz
Why (RPRX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
What's Going On With Royalty Pharma Stock Wednesday?Royalty Pharma (NASDAQ:RPRX) - Benzinga
Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones - MarketScreener
Royalty Pharma Acquires Remaining Evrysdi Royalties From PTC Therapeutics - Nasdaq
Royalty Pharma acquires final portion of Evrysdi royalty for $240 million By Investing.com - Investing.com Nigeria
PTC Therapeutics IncCo, Royalty Pharma Inv - 富途牛牛
Royalty Pharma acquires remaining royalty interest in Roche's Evrysdi for $240 million - MarketScreener
Royalty Pharma Buys Remaining Royalty Interest in Roche's Evrysdi - MarketScreener
Royalty Pharma acquires final portion of Evrysdi royalty for $240 million - Investing.com
Royalty Pharma (NASDAQ:RPRX) EVP Sells $786,400.00 in Stock - MarketBeat
Royalty Pharma stock rises after acquiring full Evrysdi royalty By Investing.com - Investing.com Canada
Royalty Pharma stock rises after acquiring full Evrysdi royalty - Investing.com
Royalty Pharma Acquires Final Portion of Evrysdi Royalty from PTC Therapeutics for $240 Million - Quiver Quantitative
Royalty Pharma acquires remaining Evrysdi royalty for $240 million - StreetInsider
A $1.9B spinal atrophy drug’s royalties just found a new owner - Stock Titan
Nuvalent’s royalty interest acquired by Royalty Pharma - MSN
Royalty Pharma PLC $RPRX Shares Sold by Marathon Asset Management Ltd - MarketBeat
Royalty Pharma announces planned legal leadership transition - MSN
Royalty Pharma Plc's (NASDAQ:RPRX) Earnings Haven't Escaped The Attention Of Investors - 富途牛牛
World Investment Advisors Takes $1.70 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Can Royalty Pharma plc (RPD) stock ride next bull market cycleReal Estate Investment Trusts & Capitalize On Fast Trends - bollywoodhelpline.com
Royalty Pharma PLC $RPRX Stock Holdings Lifted by Voya Investment Management LLC - MarketBeat
Swedbank AB Acquires 42,800 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Friedenthal Financial Acquires Shares of 29,322 Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX): Reassessing Valuation After MYQORZO’s FDA Approval Unlocks New Royalty Cash Flows - Sahm
Royalty Pharma (NASDAQ:RPRX) EVP Sells $767,600.00 in Stock - MarketBeat
Royalty Pharma Announces Planned Legal Leadership Transition - TipRanks
Royalty Pharma names McGivern as chief legal officer - StreetInsider
Royalty Pharma Plc Azioni (RPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Royalty Pharma Plc Azioni (RPRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Coyne Terrance P. | EVP & CFO |
Jan 02 '26 |
Sale |
38.42 |
69,582 |
2,673,041 |
39,760 |
| Urist Marshall | EVP, Research & Investments |
Jan 02 '26 |
Sale |
38.48 |
20,000 |
769,650 |
80,000 |
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):